IRIDEX (NASDAQ:IRIX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a report issued on Tuesday morning. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 1.9 %

NASDAQ:IRIX opened at $1.64 on Tuesday. The company has a market cap of $27.29 million, a PE ratio of -2.45 and a beta of 0.82. The business’s 50 day moving average is $1.72 and its two-hundred day moving average is $1.77. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. IRIDEX has a 52 week low of $1.27 and a 52 week high of $3.65.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The firm had revenue of $11.58 million for the quarter. During the same quarter in the previous year, the business earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.